Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia.

ABSTRACT: Dual orexin receptor antagonists (DORAs) represent a novel type of sleep medication that provide an alternative to the traditionally used positive allosteric gamma-aminobutyric acid (GABA)-A receptor modulators. Daridorexant is a new DORA that exhibited in phase 3 trials in insomnia not only a beneficial effect on sleep variables, measured objectively and assessed subjectively, but also an improvement in daytime functioning. Daridorexant was discovered through a tailored research program aimed at identifying an optimized sleep-promoting molecule with pharmacokinetic properties appropriate for covering the whole night while avoiding next-morning residual activity at efficacious doses. By specific binding to both orexin receptors, daridorexant inhibits the actions of the wake-promoting orexi

SUBMITTER: Roch C 

PROVIDER: S-EPMC8455402 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature